RMH clonoSEQ® Assay

The procurement of a next-generation sequencing (NGS)–based test assay designed for the detection and monitoring of minimal residual disease (MRD) in patients with certain haematologic malignancies, such as multiple myeloma, acute lymphoblastic leukaemia (ALL), and chronic lymphocytic leukaemia (CLL). The required goods and services include: • Provision of assay kits and reagents suitable for the intended patient population. • Use of a software platform for analysis and reporting of results. • Training and technica...